4.2 Article

Immune-Mediated Disorders Among Women Carriers of Fragile X Premutation Alleles

期刊

AMERICAN JOURNAL OF MEDICAL GENETICS PART A
卷 158A, 期 10, 页码 2473-2481

出版社

WILEY
DOI: 10.1002/ajmg.a.35569

关键词

autoimmune; FXTAS; RNA toxicity; ovarian insufficiency

资金

  1. National Institute of Health [HD036071, HD02274]
  2. Neuro Therapeutics Research Institute (NTRI) [DE019583, DA024854]
  3. National Institute on Aging [AG032119, AG032115]
  4. National Institute of Mental Health [MH077554]
  5. National Center for Research Resources [UL1 RR024146]
  6. Health and Human Services Administration on Developmental Disabilities [90DD05969]
  7. Seaside Therapeutics
  8. Roche
  9. Novartis
  10. Forest
  11. Curemark

向作者/读者索取更多资源

The relative risk of immune-mediated disorders (IMDs) among women carriers of premutation alleles is estimated by a survey for IMDs among 344 carrier women (age 19-81 years; mean 46.35 and SD 12.60) and 72 controls (age 18-87 years; mean 52.40 and SD 15.40). One hundred fifty four (44.77%) women carrier had at least one IMD, as did 20 controls (27.78%). Among women carriers, autoimmune thyroid disorder was the most common (24.4%), then fibromyalgia (10.2%), irritable bowel syndrome (IBS; 9.9%), Raynaud's phenomenon (7.6%), rheumatoid arthritis (RA; 3.8%), Sjogren syndrome (2.6%), systemic lupus erythematosus (SLE; 2.03%), multiple sclerosis (1.74%). Of 55 carriers age 40 or older with FXTAS, 72.73% had at least one IMD, compared to 46.54% of those without FXTAS (n = 159), and 31.58% of controls (n = 57). The estimated odds ratio (OR) for IMD is 2.6 (95% CI 1.2-5.6, P = 0.015) for women with FXTAS relative to those without FXTAS; the likelihood of IMD in carriers without or with FXTAS was also significantly higher than for controls (OR 2.1, 95% CI 1.1-4.2, P = 0.034; OR 5.5, 95% CI 2.4-12.5, P < 0.001, respectively). Similarly, the odds of having an IMD among carriers with FXPOI is about 2.4 times higher when compared to carriers without FXPOI (95% CI 1.1-5.0; P = 0.021). The likelihood of IMD in carriers with or without FXPOI is greater (OR 2.4, 95% CI 1.1-5.0; P = 0.021) compared to that of controls. (C) 2012 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据